Thursday, October 17, 2019 8:10:07 AM
PR Newswire • October 17, 2019
Earnings Discussion and Business Update Scheduled for 9:00 am EDT
NEW YORK and CAESAREA, Israel, Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (DRIO) today announced it will release its third quarter 2019 results on Monday, October 28, and host a conference call the same morning at 9:00 am EDT.
Dario Health (PRNewsfoto/DarioHealth Corp.)
More
The Company will discuss its third quarter 2019 operating and financial results and its outlook for 2019.
The call will be hosted by Erez Raphael, Chief Executive Officer, Olivier Jarry, President and Chief Commercial Officer, and Zvi Ben-David, Chief Financial Officer.
The live call can be accessed by dialing 1-844-369-8770 or 1-862-298-0840 (international). Participants should ask for the DarioHealth Earnings Conference Call. The conference call will also be available via live webcast at: https://www.investornetwork.com/event/presentation/54487
Conference Call Details:
Date: Tuesday, October 28, 2019
Time: 9:00am EDT
Dial-in Number: 1-844-369-8770
International Dial-in Number: 1-862-298-0840
Webcast: www.investornetwork.com/event/presentation/54487
Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through November 11, 2019. To listen to the replay, dial 1-877-481-4010 (domestic) or 1-919-882-2331 (international) and use replay passcode 54487. The webcast replay will be available through January 28, 2020.
About DarioHealth Corp.
DarioHealth Corp. (DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way. DarioHealth's cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: https://www.dariohealth.com/.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
Recent DRIO News
- Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes • PR Newswire (US) • 04/25/2024 12:30:00 PM
- Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health • PR Newswire (US) • 04/02/2024 12:30:00 PM
- DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH • PR Newswire (US) • 03/21/2024 12:30:00 PM
- New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications • PR Newswire (US) • 03/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:24:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:20:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:16:57 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/29/2024 09:03:08 PM
- DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE • PR Newswire (US) • 02/28/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:16:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/21/2024 09:09:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:30:08 PM
- Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions • PR Newswire (US) • 02/21/2024 11:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:31:35 PM
- Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET • GlobeNewswire Inc. • 01/22/2024 09:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/19/2024 09:15:52 PM
- Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support • PR Newswire (US) • 01/11/2024 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM